Multidrug resistance in aggressive lymphoproliferative disorders of T and natural-killer origin

Leukemia and Lymphoma

Volumn 30, Issue 3-4, 1998, Pages 381-387

  Drénou, Bernard ^a   Amiot, Laurence ^a   Lamy, Thierry ^a   Le Prisé, Pierre Yves ^a   Fauchet, Renée ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Acute lymphoblastic leukemia; Flow cytometry; Multidrug resistance; Non hodgkin lymphoma; Rhodamine 123

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; GLYCOPROTEIN P; RHODAMINE 123;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LARGE GRANULAR LYMPHOCYTE; LUNG RESISTANCE; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MULTIDRUG RESISTANCE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; SEZARY SYNDROME; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE;

EID: 0031870088     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057549     Document Type: Article

References (46)

1. Arceci, R. J. (1993). Clinical significiance of P-glycoprotein in multidrug resistance malignancies. Blood. 81, 2215-2222.
2. McKenna, S. L. and Padua, R. A. (1997). Multidrug resistance in leukemia. Br. J. Haematol., 96, 659-674.
3. Roninson, I. B., Chin, J. E., Choi, K. G., Gros, P., Housman, D. E., Fojo, A., Shen, V., Goettesman, M. M. and Pastan, I. (1986). Isolation of human MDR DNA sequences amplified in mutlidrug-resistant KB carcinoma-cells. Proc. Natl. Acad. Sci., 83, 4538-4542.
4. Hamada, H. and Tsuruo, T. (1986). Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci., 83, 7785-7789.
5. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V. and Deeley, R. G. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650-1654.
6. Scheper, R. J., Broxterman, H. J., Scheffer, G. L., Kaajik, P., Dalton, W. S., van Heijningen, T. H. M., van Kalken, C. K., Slovack, M. L., de Vries, E. G. E., van der Valk, P., Meijer, C. J. L. M. and Pinedo, H. M. (1993). Overexpression of a Mr 110.000 vesicular protein in Non-P-glycoprotein-mediated multidrug resistance. Cancer Res., 53, 1475-1479.
7. Scheffer, G. L., Winjgaard, P. L. J., Flens, M. J., Izquierdo, M. A., Slovak, M. L., Pinedo, H. M., Meijer, C. J. L. M., Clevers, H. C. and Scheper, R. J. (1995). The drug resistance-related protein LRP is the human major vault protein. Nature Med., 1, 578-582.
8. Chaudary, P. M. and Roninson, J. B. (1991). Expression and activity of P-Glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 66, 85-94.
9. Davey, M. W., Hargrave, R. M. and Davey, R. A. (1996). Comparison of drug accumulation in P-glycoprotein expressing and MRP-expressing human leukaemia cells. Leuk. Res., 20, 657-664.
10. Webb, M., Raphael, C. L., Asbahr, H., Erber, W. N. and Meyer, B. F. (1996). The detection of rhodamine 123 efflux at low levels of drug resistance. Br. J. Haematol., 93, 650-655.
11. Lennert, K. and Feller, A. C. (1990). Histopathologie der Non-Hodgkin Lymphome. (Nach der aktualiesierten Kiel Klassification), (Springer-Verlag. Berlin and Heidelberg).
12. Harris, N. L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J. K. C., Cleary, M. L., Delsol, G., De Wolf-Peeters, C., Falini, B., Gatter, K. C., Grogan, T. M., Isaacson, P., Knowles, D. M., Mason, D., Müller-Hermelink, H. K., Pileri, S. A., Piris, M. A., Ralfkiaer, E. and Warnke, R. A. (1994). A revised European-American Classification of lymphoid neoplasms: A proposal from the International lymphoma study group. Blood, 84, 1361-1392.
13. Neyfackh, A. (1988). Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp. Cell. Res., 174, 168-176.
14. Coon, J. S., Wang, Y., Bines, S. D., Markham, P. N., Chong, A. S. F. and Gebel, H. M. (1991). Multidrug resistance activity in human lymphocytes. Hum. Immunol., 32, 134-140.
15. Lamy, T., Grulois, I., Drénou, B., Fardel, O., Le Prisé, P. Y., Semana, G., Genetet, N. and Fauchet, R. (1994). High PgP activity measured by rhodamine 123 efflux asay in CD3. CD8. CD56 human lymphocytes and in CD3+. CD57+ large granular lymphocyte proliferative disorders. (GLPD) Br. J. Hematol., 87, 112.
16. Yuen, A. and Sikic, B. I. (1994). Multidrug resistance in lymphomas. J. Clin. Oncol., 12, 2453-2459.
17. Lamy, T., Drénou, B., Grulois, I., Fardel, O., Jacquelinet, C., Goasguen, J., Dauriac, C., Amiot, L., Bernard, M., Fauchet, R. and Le Prisé, P. Y. (1995). Multidrug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia, 9, 1549-1555.
18. Paietta, E., Andersen, J., Racevskis, J., Ashigbi, M., Cassileth, P. and Wiernik, P. H. (1995). Modulation of multidrug resistance in de novo acute myeloid leukemia: variable efficacy of reverting agents in vitro. Blood reviews, 9, 47-52.
19. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. A. G., Granick, H. R. and Sultan, S. (1985). Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative group. Ann. Intern. Med., 103, 620-625.
20. Bene, M. C., Castold, G., Knapp, W., Ludwig, W. D., Matutes, E., Orfao, A. and Van't Veer, M. B. (1995). Proposals for the immunological classification of acute leukemias. Leukemia. 9, 1783-1786.
21. Loughran, T. P. (1993). Clonal disease of large granular lymphocytes. Blood, 82, 1-14.
22. Semenzato, G., Zambello, R., Starkebaum, G., Oshimi, K. and Loughran, T. P. The lymphoproliferation disease of granular lymphocytes: Updated criteria for diagnosis. Blood. 89, 256-260.
23. Drénou, B., Lamy, T., Amiot, L., Fardel, O., Caulet-Maugendre, S., Sasportes, M., Diebold, J., Le Prisé, P. Y. and Fauchet, R. (1997). CD3-CD56+ Non Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood. 89, 2966-2974.
24. Drénou, B., Fardel, O., Amiot, L. and Fauchet, R. (1993). Detection of P-glycoprotein activity in normal and leukemic CD34 positive cells Leukemia Res., 17, 1031-1035.
25. Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Purification of nucleid acids. In Molecular cloning, (2nd ed.) Sambrook, J., Fritsch, E.F. and Maniatis, T. (eds.) (Cold Spring Harbor Laboratory Press) vol. 3, p.E.3.
26. Mac Intyre, E., D'Auriol, L., Amesland, F., Loiseau, P., Chen,. Boumsell, L., Galibert, F. and Sigaux, F. (1989). Analysis of junctionnal diversity in the preferential V-J rearrangement for fresh T-acute lymphoblastic leukemia cells by in vitro gene amplification and direct sequencing. Blood, 74, 2053-2061.
27. Jaffe, E. S., Chan, J. K. C., Su, I. J., Frizzera, G., Mon, S., Feller, A. C. and Ho, F. C. S. (1996). Report of the workshop on nasal and related extranodal angiocentric T/NK-cell lymphomas: Definitions, differential diagnosis, and epidemiology. Am. J. Surg. Pathol., 20, 103-111.
28. Emile, J. F., Boulland, M. L., Haioun, C., Kanavaros, P., Petrella, T., Delfau-Larue, M. H., Bensussan, A., Farcet, J. P. and Gaulard, P. (1996). CD5-CD56+ "TCR silent peripheral T-cell lymphomas" are natural killer cell lymphomas. Blood. 87, 1466-1473.
29. Tefferi, A., Li, C. Y., Witzig, T. E., Dhodapkar, M. V., Okuno, S. H. and Phyliky, R. L. (1994). Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood, 84, 2721-2725.
30. Sivakumaran, M., Richards, S. J. and Scott, C. S. (1996). Clinical and laboratory characteristics of chronic natural killer cell lymphocytosis Blood, 87, 1659-1560.
31. Imamura, N., Kusunoki, Y., Kawa-Ha, K., Yumura, K., Hatra, J., Oda, K., Abe, K., Dohy, H., Inada, T., Kajihara, H. and Kuramoto, A. (1990). Aggressive natural killer cell leukemia/ lymphoma: report of four cases and review of the literature. Br. Haematol., 75, 49-59.
32. Wong, K. F., Chan, J. K. C., Ng, C. S., Lee, K. C., Tsang, W. Y. W. and Cheung, M. M. C. (1992). CD56 (NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. Hum. Pathol., 23, 798-804.
33. Kanavaros, P., Lescs, M. C., Brière, J., Divine, M., Galateau, F., Joab, I., Bosq, J., Farcet, J. P., Reyes, F. and Gaulard, P. (1993). Nasal T-cell lymphoma: A clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood, 81, 2688-2695.
34. Kern, W. F., Spier, C. M., Hanneman, E. H., Miller, T. P., Matzner, M. and Grogan, T. M. (1992). Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood. 79, 2432-2437.
35. + NK lymphomas: clinicopathological features and prognosis. Br. J. Haematol., 97, 821-829.
36. Chan, J. K. C., Sin, V. C., Ng, C. S., Tsang, W. Y. W., Chan, C. H., Cheung, M. M. C. and Lau, W. H. (1997). Non nasal lymphoma expressing the natural killer cell marker CD56: a clinicopathological study of 49 cases of an uncommon agressive neoplasm. Blood. 89, 4501-4513.
37. Yumamoto, T., Iwasaki, T., Watanabe, N., Oshimi, K., Naito, M., Tsuruo, T. and Kobayashi, Y. (1993). Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte-proliferative disorders. Blood, 81, 1342-2356.
38. Yamaguchi, M., Kita, K., Miwa, H., Nishii, K., Oka, K., Ohno, T., Shirakawa, S. and Fukumoto, M. (1995). Frequent expression of P-glycoprotein/MDR1 by Nasal T-Cell lymphoma cells. Cancer, 76, 2351-2356.
39. Weisburg, J. H., Curcio, M., Caron, P. C., Raghu, G., Mechetner, E. B., Roepe, P. D. and Scheinberg, D. A. (1996). The multidrug resistance phenotype confers immunological resistance. J Exp Med. 183, 2699-2704.
40. Raghu, G., Park, S. W., Roninson, I. B. and Metcheter, E. B. (1996). Monoclonal antibodies against P-glycoprotein and MDR1 gene product inhibit interleukin 2 release from PHA-activated lymphocytes. Exp. Hematol., 24, 1258-1264.
41. Chong, A. S. F., Markham, P. N., Gebel, H. M., Bines, S. D. and Coon, J. S. (1993). Diverse multidrug-resistance modification agents inhibit cytolytic activity of natural killer cells. Cancer, Immuno. Immunother., 36, 133-136.
42. Matutes, E., Brito-Babapulle, V., Swansbury, J., Ellis, J., Morilla, R., Dearden, C., Sempere, A. and Catovsky, D. (1991). Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 78, 3269-3274.
43. Burger, H., Nooter, K., Sonneveld, P., Van Wingerden, K. E., Zaman, G. J. R. and Stoter, G. (1994). High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. Br. J. Haematol., 88, 348-356.
44. Diamandidou, E., Cohen, P. R. and Kurzrock, R. (1996). Mycosis fungoide and Sezary syndrome. Blood, 88, 2385-2409.
45. Burger, H., Nooter, K., Zaman, G. J. R., Sonneveld, P., van Wingerden, K. E., Oostrum, R. G. and Stoter, G. (1994). Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia, 8, 990-997.
46. Michieli, M., Damiani, D., Ermacora, A., Raspadori, D., Michelutti, A., Grimaz, S., Fanin, R., Russo, D., Lauria, F., Masolini, P. and Baccarani, M. (1997). P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukemic blast cells. Br. J. Haematol., 96, 356-365.